Suppr超能文献

基于人群的乳腺钼靶筛查:“知情选择”对向个体全面披露益处、危害、局限性和后果的要求难道可以降低吗?

Population-based mammographic screening: does 'informed choice' require any less than full disclosure to individuals of benefits, harms, limitations and consequences?

作者信息

Ward J

机构信息

Needs Assessment & Health Outcomes Unit, Central Sydney Area Health Service, New South Wales.

出版信息

Aust N Z J Public Health. 1999 Jun;23(3):301-4. doi: 10.1111/j.1467-842x.1999.tb01260.x.

Abstract

Mammographic screening is a public health intervention with benefits, harms and consequences. Assuming technical excellence and at least 70% participation, mammographic screening of women aged 50 years or over will reduce breast cancer mortality by 24%. Before the introduction of mammographic screening in Australia, the mortality rate from breast cancer for women in the target age group was 69.0 per 100,000. On the basis of this relative risk reduction, breast cancer mortality would be reduced to 46 per 100,000. However, for every breast cancer death averted, 10 additional cases of breast cancer will be diagnosed. As it is unknowable who will benefit from mammographic screening, it is unethical to claim that any given individual has been 'saved' through participation, especially in the absence of evidence that all-cause mortality will change. As women misunderstand their risks of breast cancer and the benefits and limitations of mammographic screening, public education is needed. As an individual's choice about screening is affected by the way benefits are framed, our public messages must be carefully scrutinised. It is impossible otherwise to assert that women are making an 'informed choice'. The decision of women who decline to participate must be respected. Public health expertise is crucial to ensure the rhetoric of 'informed choice' in cancer screening is realised.

摘要

乳腺钼靶筛查是一项具有益处、危害和后果的公共卫生干预措施。假设技术精湛且参与率至少达到70%,对50岁及以上女性进行乳腺钼靶筛查可使乳腺癌死亡率降低24%。在澳大利亚引入乳腺钼靶筛查之前,目标年龄组女性的乳腺癌死亡率为每10万人69.0例。基于这种相对风险降低,乳腺癌死亡率将降至每10万人46例。然而,每避免一例乳腺癌死亡,就会额外诊断出10例乳腺癌病例。由于无法知道谁将从乳腺钼靶筛查中受益,声称任何特定个体通过参与筛查而“获救”是不道德的,尤其是在没有证据表明全因死亡率会改变的情况下。由于女性误解了她们患乳腺癌的风险以及乳腺钼靶筛查的益处和局限性,因此需要进行公众教育。由于个人对筛查的选择会受到益处表述方式的影响,我们的公共信息必须经过仔细审查。否则就无法断言女性做出了“明智的选择”。必须尊重拒绝参与筛查的女性的决定。公共卫生专业知识对于确保癌症筛查中“明智选择”的言辞得以实现至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验